Experience

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $281.75 million initial public offering by 1Life Healthcare, Inc…

Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition,…

Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary shares, each 10 ADSs representing 23 ordinary shares, for total…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…